Soliris may prove to be a new treatment for dry macular degeneration.
Originally used to treat a rare blood disorder, Soliris is the latest drug being tested as a treatment for dry macular degeneration. Alexion Pharmaceuticals is starting clinical trials in Soliris (eculizumab) at the Bascom Palmer Eye Institute at the University of Miami School of Medicine.
Dr. Phil Rosenfeld is the lead researcher during this Phase II clinical trial.
It is hoped that Soliris will prove to be a treatment for dry macular degeneration in the early stages of the eye disease and will inhibit the progression of the disease.
For details on the clinical trial of Soliris for dry macular degeneration visit www.clinicaltrials.gov/ct2/show/NCT00935883?term=soliris&rank=3.